CN Patent

CN113493480B — 一种瑞德西韦异构体的制备及其分析方法

Assigned to Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd · Expires 2025-04-15 · 1y expired

What this patent protects

本发明提供一种瑞德西韦异构体及其制备和分析方法，通过该制备方法可以得到高纯度的异构体化合物，且本发明提供的分析方法可以实现异构体与瑞德西韦的有效分离，检测方法简便﹑快速﹑准确﹑灵敏度高﹑重复性好﹑准确度好，适合工业化生产使用。

USPTO Abstract

本发明提供一种瑞德西韦异构体及其制备和分析方法，通过该制备方法可以得到高纯度的异构体化合物，且本发明提供的分析方法可以实现异构体与瑞德西韦的有效分离，检测方法简便﹑快速﹑准确﹑灵敏度高﹑重复性好﹑准确度好，适合工业化生产使用。

Drugs covered by this patent

Patent Metadata

Patent number
CN113493480B
Jurisdiction
CN
Classification
—
Expires
2025-04-15
Drug substance claim
No
Drug product claim
No
Assignee
Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.